|
|
|
|
|
|
by hentrep
1110 days ago
|
|
|
I’m writing this live from the ASCO meeting where this was just presented. Osimertinib (TAGRISSO) has truly transformed the way we treat EGFR-mutant NSCLC, having repeatedly redefined standards of care. I don’t have a source handy, but osi used to hold a record in oncology as being the fastest drug to go from IND (trial-enabling) to approval - less than 18 months. Osimertinib did $5.44B in global sales last year, leading AstraZeneca’s oncology portfolio [0] [0] https://www.astrazeneca.com/content/dam/az/PDF/2022/fy/Full-... |
|
|